These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 27625193)
1. Viral hepatitis: Response-guided strategy to reduce DAA duration for hepatitis C. Ray K Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):558. PubMed ID: 27625193 [No Abstract] [Full Text] [Related]
2. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. Lawitz EJ; Membreno FE J Gastroenterol Hepatol; 2014 Aug; 29(8):1574-81. PubMed ID: 24852401 [TBL] [Abstract][Full Text] [Related]
3. Prevention and management of treatment failure to new oral hepatitis C drugs. Benítez-Gutiérrez L; Barreiro P; Labarga P; de Mendoza C; Fernandez-Montero JV; Arias A; Peña JM; Soriano V Expert Opin Pharmacother; 2016 Jun; 17(9):1215-23. PubMed ID: 27149603 [TBL] [Abstract][Full Text] [Related]
4. New hepatitis C therapies for special patient populations. Soriano V; Labarga P; de Mendoza C; Fernández-Montero JV; Esposito I; Benítez-Gutiérrez L; Peña JM; Barreiro P Expert Opin Pharmacother; 2016; 17(2):217-29. PubMed ID: 26595348 [TBL] [Abstract][Full Text] [Related]
5. [Development status of DAA against hepatitis C]. Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942 [No Abstract] [Full Text] [Related]
6. Perspectives on treating hepatitis C infection in the liver transplantation setting. Chen T; Terrault NA Curr Opin Organ Transplant; 2016 Apr; 21(2):111-9. PubMed ID: 26927201 [TBL] [Abstract][Full Text] [Related]
7. [Recent advances in the treatment of hepatitis C in 2016]. Luo BF; Wei L Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):175-180. PubMed ID: 28482403 [TBL] [Abstract][Full Text] [Related]
8. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixco C; Decaestecker J; de Galocsy C; Janssens F; Van Overbeke L; Van Steenkiste C; D'Heygere F; Cool M; Wuyckens K; Nevens F; Robaeys G J Viral Hepat; 2017 Nov; 24(11):976-981. PubMed ID: 28504854 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Belperio PS; Shahoumian TA; Mole LA; Backus LI Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789 [TBL] [Abstract][Full Text] [Related]
10. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV Antivir Ther; 2016; 21(5):465. PubMed ID: 27509356 [No Abstract] [Full Text] [Related]
11. OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma. Chtioui H Hepatology; 2017 Dec; 66(6):2091. PubMed ID: 28960433 [No Abstract] [Full Text] [Related]
12. [Current management of hepatitis C]. Lange CM Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda. Singal AK; Venkata KVR; Jampana S; Islam FU; Anderson KE Am J Med Sci; 2017 Jun; 353(6):523-528. PubMed ID: 28641714 [TBL] [Abstract][Full Text] [Related]
14. [Host factors and viral factors in hepatitis C treatment]. Sakamoto M; Enomoto N Nihon Rinsho; 2015 Feb; 73(2):208-12. PubMed ID: 25764672 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Dore GJ; Feld JJ Clin Infect Dis; 2015 Jun; 60(12):1829-36. PubMed ID: 25761867 [TBL] [Abstract][Full Text] [Related]
16. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886 [TBL] [Abstract][Full Text] [Related]
17. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3]. Jung YK Korean J Gastroenterol; 2016 Mar; 67(3):132-6. PubMed ID: 26996182 [TBL] [Abstract][Full Text] [Related]
19. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. El Sherif O; Afhdal N; Curry M J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634 [TBL] [Abstract][Full Text] [Related]
20. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? Visentini M; Fiorilli M; Casato M Expert Rev Hematol; 2017 Aug; 10(8):719-727. PubMed ID: 28675071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]